FungiScope - A Global Emerging Fungal Infection Registry
NCT ID: NCT01731353
Last Updated: 2023-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2003-03-31
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. To determine the fungal species causing invasive fungal infection in different parts of the world.
2. To determine the clinical pattern of disease and document procedures performed for confirmation of the diagnosis.
3. To describe the therapeutic regimens used and their efficacy.
4. To share clinical isolates among the contributors of Fungiscope.
5. To develop molecular biology tools for identification of strains in histopathologically proven invasive fungal infection.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Emerging fungal infections
Web-based registry of invasive infections by emerging fungi
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Endemic fungal infection such as coccidioidomycosis or histoplasmosis
* Colonisation or other non-invasive infection
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Basilea Pharmaceutica
INDUSTRY
Cidara Therapeutics Inc.
INDUSTRY
F2G Biotech GmbH
INDUSTRY
Matinas Biopharma, Inc
INDUSTRY
University of Cologne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Oliver Cornely, MD
Dr. med.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Oliver A. Cornely, Professor
Role: PRINCIPAL_INVESTIGATOR
University Hospital of Cologne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Cologne
Cologne, North Rhine-Westphalia, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Oliver A Cornely, Prof.
Role: primary
Danila Seidel, PhD
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Koehler P, von Stillfried S, Garcia Borrega J, Fuchs F, Salmanton-Garcia J, Pult F, Boll B, Eichenauer DA, Shimabukuro-Vornhagen A, Kurzai O, Boor P, Kochanek M, Cornely OA. Aspergillus tracheobronchitis in COVID-19 patients with acute respiratory distress syndrome: a cohort study. Eur Respir J. 2022 May 5;59(5):2103142. doi: 10.1183/13993003.03142-2021. Print 2022 May.
Hassler A, Lieb A, Seidel D, Cesaro S, Greil J, Klimko N, Khostelidi S, Solopova G, Ogunc D, Duran Graeff L, Cornely OA, Vehreschild MJ, Lehrnbecher T. Disseminated Fusariosis in Immunocompromised Children-Analysis of Recent Cases Identified in the Global Fungiscope Registry. Pediatr Infect Dis J. 2017 Feb;36(2):230-231. doi: 10.1097/INF.0000000000001396.
Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Racil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JH, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild MJGT; VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016 Jul;16(7):828-837. doi: 10.1016/S1473-3099(16)00071-2. Epub 2016 Mar 9.
Related Links
Access external resources that provide additional context or updates about the study.
FungiScope - A Global Emerging Fungal Infection Registry
FungiQuest - Search Engine for rare fungal infection
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Fungi001
Identifier Type: -
Identifier Source: org_study_id